| __timestamp | Sanofi | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8565000000 | 7751000 |
| Thursday, January 1, 2015 | 9496000000 | 10251000 |
| Friday, January 1, 2016 | 9592000000 | 9575000 |
| Sunday, January 1, 2017 | 10164000000 | 10912000 |
| Monday, January 1, 2018 | 9934000000 | 11049000 |
| Tuesday, January 1, 2019 | 9883000000 | 11646000 |
| Wednesday, January 1, 2020 | 9390000000 | 13265000 |
| Friday, January 1, 2021 | 9555000000 | 25805000 |
| Saturday, January 1, 2022 | 10539000000 | 35182000 |
| Sunday, January 1, 2023 | 10765000000 | 94999000 |
| Monday, January 1, 2024 | 9183000000 |
Unleashing insights
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Sanofi and Viridian Therapeutics, Inc. have taken different paths in optimizing these costs. Sanofi, a global leader, has consistently maintained high SG&A expenses, averaging around $9.8 billion annually. In contrast, Viridian Therapeutics, a smaller player, has kept its SG&A costs significantly lower, averaging just $23 million per year.
From 2014 to 2023, Sanofi's SG&A expenses grew by approximately 26%, while Viridian's expenses surged by over 1,100%, reflecting its rapid expansion. Despite this growth, Viridian's expenses remain a fraction of Sanofi's, highlighting its lean operational model. This comparison underscores the diverse strategies companies employ to manage costs, with Sanofi leveraging scale and Viridian focusing on agility.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Viridian Therapeutics, Inc.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Sanofi or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Sanofi or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?
Sanofi and Grifols, S.A.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.